Abstract: The invention concerns a method and a reagent kit for detecting cells in a biological sample using a double-fluorescence technique and the diagnostic and therapeutic application of amino acid sequence-specific antibodies against the urokinase receptor having a high affinity for tumour cell-expressed receptors.

Abstract: The present invention relates to isolation of a novel Hepatitis C virus, more particularly, the present invention relates to a viral class Hepatitis C, polypeptides, polynucleotide, vaccine and antibodies derived there from.

Abstract: Nucleic acid sequences, oligonucleotides and a method for detection of SRSV, in particular, a virus which belongs to Genotype II (GII), in clinical examinations, public health examinations, food evaluations and food poisoning examinations are provided.

Abstract: Methods of identifying a compound that inhibit, enhance and/or misdirect assembly of a viral capsid include providing fluorescently-labeled capsid polypeptides labeled with a fluorescent dye that changes fluorescence at high concentration, wherein assembly of the capsid polypeptides into the viral capsid results in juxtaposition of at least one of the N-terminus and C-terminus of the capsid polypeptides. In vitro assembly reactions are performed utilizing the labeled capsid polypeptide in the presence of the at least one test compound, and an amount of fluorescence is detected at at least one time point following induction of assembly, wherein the induction of assembly is detected as a change in the fluorescence of the sample.

Abstract: The present invention refers to a polynucleotide comprising the nucleic acid sequence as depicted in SEQ ID NO:1, 2 or 3 or the fragment or derivative thereof, or a polynucleotide hybridizing with the nucleic acid sequence as depicted in SEQ ID NO:1, 2 or 3. The present invention further refers to polypeptides encoded by the nucleic acid sequence or the fragment or derivative thereof as depicted in SEQ ID NO:1, 2 or 3. The polynucleotides and polypeptides may be used as medicaments, vaccines or diagnostic substances, preferably for the treatment, prevention or diagnostic of HIV infections.

Abstract: The present invention relates to a WSSV peptide, which comprises a peptide sequence as set forth in SEQ ID NO: 1 and can be used as target peptide for WSD immunodetection in crustaceans. In addition, the present invention also provides a WSSV nucleotide sequence, which comprises a nucleotide sequence encoding the peptide sequence as set forth in SEQ ID NO: 1, and can be used as a detection target for WSD in crustaceans. On the other hand, the present invention can be applied in a WSSV detection method using the peptide or nucleotide sequences as targets. The WSSV peptide of the present invention is highly expressed in the hosts. The sensitivities of the WSSV detection using the target peptide in the invention are therefore greatly increased in comparison to the traditional detection target.

Abstract: Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.

Abstract: The present invention relates to cupredoxin, specifically Pseudomonas aeruginosa azurin, and/or Pseudomonas aeruginosa cytochrome C551 and their use in inhibiting of viral infection, and in particular infection of mammalian cells by the Human Immunodeficiency Virus (HIV). The invention also relates to variants and derivatives of cupredoxin and cytochrome c that retain the ability to inhibit viral infection, and in particular infection by the Human Immunodeficiency Virus (HIV). The invention also relates to research methods for studying viral and bacterial infection in mammalian cells.

Abstract: Methods and compositions for identifying or detecting viral nucleic acids in a host cell are described. DNA fragments are bound to DNA-binding protein in a host cell and enriched using immunoprecipitation. The enriched fragments are then hybridized to a microarray containing sequences complementary to proviral DNA and genomic DNA.

Abstract: Embodiments of the present invention generally relate to a novel attenuated infectious bronchitis virus (IBV) of GA-98 isolate. Further, other embodiments of the present invention generally relate to methods of immunizing avian against an infectious bronchitis virus. As well, further embodiments relate to method of making a vaccine and/or immunogenic composition for protecting avian, such as poultry, from an infectious bronchitis virus of strain GA-98.

Abstract: Multiple branch peptide constructions formed from peptide-branches derived from the envelope transmembrane glycoprotein gp41 of HIV, and including the consensus sequence RQGY preceded by 0 to 4 amino acid residues and succeeded by 0 to 4 amino acid residues, most preferably RQGYS, show increased receptor affinity and prevent cell-to-cell fusion. They have a direct virostatic effect. Because they present the same peptide sequence several times, these MBPCs are able to neutralize in vitro the different steps of virus envelope/cell membrane fusion, and infected cell membrane/uninfected cell membrane fusion of several strains of HIV-1 and HIV-2. These results open a potential use in treatment of HIV infection.

Abstract: The present invention provides particles for the presentation of haptens for the purpose of eliciting an immune response. The amino acid sequences of the monomers which make up the particles are derived from duck hepatitis B virus core protein. The particles may also deliver nucleic acids. The nucleic acids may be delivered for the purpose of enhancing an immune response, or for other purposes such as gene therapy.

Abstract: The invention is a method for the development of a platform that enables the efficient and simultaneous creation of multiple detection assays. The invention entails the use of any bacteriophage, modified to carry a reporter gene, to which any analyte-recognizing moiety is attached via the capsid. The modified bacteriophage is used to attach to the target analyte. This attachment is identified via bacteriophage amplification in a helper bacteria strain with subsequent production and detection of the reporter gene.

Abstract: This invention is concerned with a peptide tag having sequence SSTSSDFRDR or GVSSTSSDFRDR derived from transactivator protein E2 of Bovine Papillomavirus type 1, and the fusion polypeptide containing said peptide tag, and the expression vector comprising the oligonucleotide sequence encoding said peptide tag. The invention relates also to the antibodies specific for the peptide tag and the methods for detecting and purifying tagged proteins.

Abstract: The present invention provides isolated mammalian GalR3 receptors, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the receptors using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptors and are useful for treating medical conditions caused or mediated by galanin. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian GalR3 receptors.